Live
- Sharad Pawar to cast vote in Baramati after a decade
- Difference Between Business Credit Score and Personal Credit Score
- Indian Bank posts 55% jump in Q4 net profit, declares dividend of Rs 12 per share
- Govt showcases India as 365-day tourist destination at Arabian Travel Mart
- Pulwama to Poonch - Congress not learning from past mistakes, experts reckon
- ISRO moves ahead in development of 2,000 kN thrust semi-cryogenic engine
- FLiRT Covid variants: No need for panic or extra caution, say experts
- Rudrabhishekam worship by devotees
- Wipro, Microsoft to launch GenAI-powered assistants for financial services
- ICICI Bank now lets NRIs use international numbers for UPI payments in India
AstraZeneca Pharma India to launch cancer drug with brand name, 'Calquence' on October 21
AstraZeneca Pharma India
Drug firm AstraZeneca Pharma India on Thursday said it would launch its Acalabrutinib 100 mg capsules, used for the treatment of various types of blood cancers, under the brand name 'Calquence' in the country on October 21, 2020.
Drug firm AstraZeneca Pharma India on Thursday said it would launch its Acalabrutinib 100 mg capsules, used for the treatment of various types of blood cancers, under the brand name 'Calquence' in the country on October 21, 2020.
The company in a regulatory filing said, We refer to our earlier communication dated March 12, 2020, intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (Calquence®). With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch Calquence® in India on October 21, 2020."
It added, Acalabrutinib100mg capsules (Calquence®) is:
1) Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
2) Indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
The capsules are indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), AstraZeneca Pharma India said in a filing to the BSE.
Shares of AstraZeneca Pharma India Ltd on Thursday closed 0.61 per cent lower at Rs 4,266.65 apiece on the BSE.
